Bharat Biotech on Monday said the firm is setting up four vaccine manufacturing facilities with a combined capacity of 700 million doses per annum
How was the nationwide dry run carried out, the next steps in the vaccine roll-out, findings from a large-scale UK study on the new variant, and more-news relevant to India's fight against Covid-19
Health Minister Harsh Vardhan termed it a 'watershed moment in India's battle against Covid-19'
First a scientist and then a businessman, founder chairman Krishna Ella quit his faculty position at the Medical University of South Carolina in Charleston, United States, in 1996 to return to India
While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India
Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants
Indian Council of Medical Research (ICMR) on Sunday said data generated through pre-clinical studies and various phases of clinical trial shows Covaxin is 'safe'
With the government approving two Covid-19 vaccines for emergency use, Serum Institute said it is ready to roll out Covishield vaccine in India in the coming weeks
"Congress and the Opposition is not proud of anything Indian. They should introspect about how their lies on the Covid-19 vaccine will be used by vested interest groups for their own agendas," he said
Some Congress leaders raised serious concern over the grant of approval to Bharat Biotech's Covid-19 vaccine for restricted use, saying it is "premature" and can prove dangerous
Delhi Chief Minister Arvind Kejriwal said that approval for the emergency use of two "made in India" vaccines will give a positive direction to the country's fight against coronavirus
World Health Organisation (WHO) has welcomed India's decision giving emergency use authorisation to Covid-19 vaccines, informed Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia
Prime Minister Modi lauded scientists of the country after DCGI gave approval to Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use
Bharat Biotech on Sunday said the approval for emergency use of its Covid-19 vaccine-- Covaxin-- is a giant leap for innovation and novel product development in India
Modi said it will make every Indian proud that both the vaccines are made in India
Drug Controller General of India (DCGI) V.G. Somani on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use
Serum Institute of India CEO Adar Poonawalla on Sunday said the Oxford-AstraZeneca COVID-19 vaccine 'Covishield' is ready to roll out in the coming weeks. Poonawalla's remarks came soon after after India's drugs regulator approved Covishield for restricted emergency use. "Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks," Poonawalla tweeted. "Thank you Hon. Sri @narendramodi Ji, Hon. Sri @drharshvardhan Ji, @MoHFW_INDIA @ICMRDELHI @DBTIndia #DCGI_India @UniofOxford @AstraZeneca @gavi @GaviSeth @gatesfoundation and @BillGates for your support," he added.
The Phase III human clinical trials of Covaxin, which began in mid-November last year, require 26,000 volunteers across India
This comes a day after giving similar direction for the Oxford Covid-19 vaccine
US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee